Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PID with hypo- or agammaglobulinemia requiring IgG replacement therapy~* Intravenous IgG (IVIG) therapy at regular 3- or 4-week intervals at a stable dose for at least 3 doses prior to signing of informed consent~* Written informed consent~Exclusion Criteria:~* Newly diagnosed PID, i.e., subjects who have not previously received immunoglobulin replacement therapy~* Ongoing serious bacterial infections (SBIs: pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess) at the time of screening~* Ongoing or history of concomitant malignancies of lymphoid cells such as lymphocytic leukemia, non-Hodgkin's lymphoma, and immunodeficiency with thymoma~* Allergic or other severe reactions to immunoglobulins or other blood products recorded in the past 3 months or at the time of screening~* Pregnancy or nursing mother~* A positive result at screening on any of the following viral markers: human immunodeficiency virus-1 (HIV-1), HIV-2, hepatitis C virus, or hepatitis B virus~* Participation in a study with other investigational product during this study and within 3 months prior to screening~* Subjects who donated blood (200 mL within one month or 400 mL within 3 months prior to screening), or planning to donate blood during the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).